Skip to content

Mechanisms supporting Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder: A randomized, controlled clinical trial

The aim of this study is to determine if a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with an alcohol use disorder (AUD).

Eligible participants will be randomly allocated into either a high or low psilocybin dose group. All participant will be paired with a therapist and will receive up to 8 hours of preparation work prior to dosing. Following dosing participants will receive 5 weekly therapy sessions.

Clinical, behavioral and neuroimaging measures will be completed at various time points throughout the study.

null

Participation Requirements

  • Sex:

    Male, Female, Intersex

  • Eligible Ages:

    22 to 65

Participation Criteria

Inclusion Criteria:
- Aged 22-65
- Regularly consume alcohol and wish to decrease consumption
- Limited lifetime hallucinogen use
Exclusion Criteria:
- Diagnosis of; schizophrenia, bipolar disorders, or active suicidal ideation
- Currently pregnant, nursing, or trying to become pregnant

Study Location

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contact Study Team

Study Sponsored By
University of Calgary
Participants Required
More Information
Study ID: REB23-0666